Effects of High Estrogen Levels on Monocyte Chemoattractant Protein-1 and Wound Healing.

Herein, we tested the effects of high levels of supplemental estrogen treatment on cutaneous wound healing. Female mice were implanted with a 17β-estradiol (E) secreting pellet or placebo before receiving a full-thickness dermal excisional wound. Mice receiving the E pellet attained hormone levels that are comparable to those achieved during pregnancy. At 1, 3, and 5 days after injury, the dermal excision wound was examined for their histologic appearance, rate of closure, and chemokine levels. Wound closure, assessed by percent reepithelialization, was slower in E-treated mice relative to placebo (42.6%±6.6% vs. 70.0%±5.3%, respectively, 3 days after injury). In addition, there was a marked reduction in the subepithelial inflammatory infiltrate and granulation tissue in E-treated mice relative to placebo. Wound levels of monocyte chemoattractant protein-1 (MCP-1) were increased by 3 days after injury and continued to rise at 5 days after injury in placebo-treated mice (<0.01). By contrast, MCP-1 levels were significantly reduced at 3 and 5 days after injury in E-treated mice relative to placebo-treated controls (<0.01). This attenuation could be reversed by treatment with an estrogen receptor antagonist. High levels of estrogen are able to suppress normal wound closure. Dermal wound healing can be altered by manipulating the gonadal steroid hormone levels. In particular, high levels of estrogen can be utilized to slow down the rate of wound healing through a reduction in the inflammatory response.